IARS1 and prostate cancer: Our previous results with prostate cancer cell lines have shown that interaction of testosterone-BSA with mARs is not influenced (at the level of binding or the resulting signaling cascade and secretion) by antiandrogens [6,9] Therefore, to eliminate a possible interaction of BSA conjugated ligand with iARs, we used 10-4M cyproterone acetate in the binding experiments.